Abstract This 2022 European Atherosclerosis Society lipoprotein (a)[Lp (a)] consensus
statement updates evidence for the role of Lp (a) in atherosclerotic cardiovascular disease …

version of the Guidelines, which is freely available via the ESC and EAS websites and
hosted on their journals' websites (EHJ and Atherosclerosis Journal). The National Cardiac …

Objective: Lp (a)(lipoprotein [a]) concentrations are associated with atherosclerotic
cardiovascular disease (ASCVD), and new therapies that enable potent and specific …

Importance Lipoprotein (a)(Lp [a]) is a low-density lipoprotein (LDL) cholesterol–like particle
bound to apolipoprotein (a). This novel marker of cardiovascular disease acts through …

There is a need to identify high-risk features that predict early-onset atherosclerotic
cardiovascular disease (ASCVD). The authors provide insights to help clinicians identify and …

Abstract Lipoprotein (a)[Lp (a)] is a well-recognized, independent risk factor for
atherosclerotic cardiovascular disease, with elevated levels estimated to be prevalent in …

Background Elevated lipoprotein (a) is a genetic risk factor for cardiovascular disease in
general population studies. However, its contribution to risk for cardiovascular events in …

Abstract Aims Lipoprotein (a)[Lp (a)] is elevated in 20–30% of people. This study aimed to
assess the effect of statins on Lp (a) levels. Methods and results This subject-level meta …

Background Current guidelines target low-density lipoprotein cholesterol (LDL-C)
concentrations to reduce atherosclerotic cardiovascular disease (ASCVD) risk, and yet …

Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of death
worldwide. Low-density lipoprotein cholesterol (LDL-C) is a well-established mediator of …